Navigation Links
Sanomedics International Holdings, Inc. appoints new Chairman of the Board and installs new Director of Business Development.
Date:9/11/2013

MIAMI, Sept. 11, 2013 /PRNewswire/ -- Sanomedics International Holdings, Inc. (OTCQB: SIMH), a Miami based medical technology holding Company that focuses on game changing products, services and ideas, announces that William Lerner, Esq., a board member of the Company since March 2013, has been appointed to serve as the chairman of the executive board of the Company.

Keith Houlihan, Co-founder and President of Sanomedics, stated, "We are fortunate to have someone of Mr. Lerner's caliber as our Chairman. Mr. Lerner will help position us for a listing upgrade and strengthen our corporate governance requirements. He will serve the best interests of the company during this time of growth and we look forward to working with Mr. Lerner."

Mr. Lerner, a graduate of Cornell University and of the New York University School of Law, is a member of the bars of New York and Pennsylvania, with a Peer Rating for more than 25 years of AV (Martindale Hubbell). For over the last five years, Mr. Lerner has been engaged in the private practice of corporate and securities law in New York and Pennsylvania. Since 2006, Mr. Lerner has served as a director/trustee of The Daily Income Fund, a diversified, open-end management investment company, and also serves as the Chairman of the Compliance and Risk Committee. Mr. Lerner also served as Branch Chief of the Enforcement Division at the SEC and a former officer and director of compliance at the American Stock Exchange.

Mr. Lerner is also a director of National Holdings Corporation, a holding company for National Securities Corporation, vFinance Investments, Inc., National Asset Management, Inc. and National Insurance Corporation. National Securities and vFinance are broker-dealers registered with the Securities and Exchange Commission, and members of FINRA and SIPC. National Asset Management is an SEC registered investment adviser, and National Insurance provides a full array of fixed insurance products.

Additionally the Company announces the promotion of Mr. Mark Miklos as General Manager and Director of Business Development for the newly acquired company Prime Time Medical.

"Mark is bringing more than 20+ years of building healthcare businesses, a proven ability to create and pursue new markets", stated Keith Houlihan, Co-founder and President of Sanomedics. "Having Mark will be a valuable asset to the Sanomedics family as we look to expand our market presence through organic and acquired growth."

Mark was the founder and President of Prime Time Medical Inc. since 2009 up to the recent purchase by the Company.  Prior to 2009 he has served as CEO of Respiratory Supply, Pinellas, Florida and Director of Business Development for Diabetic and Respiratory Supply of USA/CCS Medical, in Clearwater, Florida. Mark holds a BS degree in accounting and computer science from Troy State University, in Troy Alabama.

About Sanomedics International Holdings, Inc.

Sanomedics International Holdings, Inc. (SIMH) is a medical technology holding company that focuses on game changing products, services and ideas - a place where physicians, entrepreneurs, and medical companies can work together to drive innovative technologies through concept, development, and ultimately commercialization. We plan to grow our existing business organically and through strategic acquisitions specifically relating to sleep disorder diagnosis treatments. Sanomedics seeks to acquire sleep therapy operating businesses and our strategy is to integrate a portfolio of world-class products and service providers in the growing Sleep Apnea market. Our goal is to provide Sleep Apnea patients with a reliable and integrated "end-to-end" service platform.

Forward Looking Statements
This press release may contain statements which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the intent, belief or current expectations of the Company, its directors, or its officers with respect to the future operating performance of the Company. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties (for example, the risk that the acquisition of Prime Time is not consummated), and that actual results may differ materially from those in the forward-looking statements as a result of various factors. The Company's periodic filings with the Securities and Exchange Commission should be viewed for a complete understanding of risk and uncertainty.

Contact: Keith Houlihan, 305-433-7814, keith@sanomedics.com


'/>"/>
SOURCE Sanomedics International Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. DSMs Marcel Lubben to Keynote SCD-iBIOs Second International Forum
2. SCD-iBIO Announces Second International Forum on Commercializing Global Green
3. iLab Solutions to Present SRA International Webinar for Research Administrators
4. MiMedx Plantar Fasciitis Study Published In The Foot & Ankle International Journal
5. RIAO/OPTILAS, ETOP Draw International Photonics Community to Portugal
6. Bayer CropScience Presents on Bee Health and Stewardship at International Pollinator Conference
7. Nerium International Names Krupp Kommunications, Inc. (K2) Public Relations Agency of Record
8. Fortune 500 Company Contracts with Wireless Analytics to Extend Wireless Expense Management & Mobility Management Services Internationally
9. Dyadic International Reports Second Quarter 2013 Financial Results
10. Novus International to Present Scientific Findings on Prebiotics during Aquaculture Europe 2013
11. Mimedx Scientific Study Is Electronically Published in The International Wound Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... -- Research and Markets has announced the addition of ... their offering. ... The report provides separate comprehensive analytics for the US, ... World. Annual estimates and forecasts are provided for the period 2015 ... markets. Market data and analytics are derived from primary and secondary ...
(Date:2/17/2017)...  If only one in every hundred cells ... to chemotherapy, thousands of cancer cells would remain ... finding these mutations in ever-smaller subpopulations of tumor ... in blood — to guide treatment decisions and ... however, detecting these genetic anomalies may be more ...
(Date:2/16/2017)... ... ... EIT Digital has launched work to develop a new Smart IOT ... to get under way for the framework, which is designed to reduce the use ... to be transferred eventually to other industries that also require efficient IoT and management ...
(Date:2/16/2017)... PARK, Calif. and GREENWICH, ... Capital, a private investment firm focused on venture ... announced the promotion of Josh Richardson , ... focuses on investments in biotechnology companies.  He is ... has played important roles in Longitude,s investments in ...
Breaking Biology Technology:
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
(Date:2/2/2017)... 1, 2017  Central to its deep commitment ... worldwide, The Japan Prize Foundation today announced the ... pushed the envelope in their respective fields of ... scientists are being recognized with the 2017 Japan ... only contribute to the advancement of science and ...
Breaking Biology News(10 mins):